
 <p><b>Form PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office</p> <p style="text-align: center;"><b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)</p>										Atty. Docket No. 55099-A-PCT-US /JPW/AJM/AJD		Serial No. 09/664,485			
<b>U.S. PATENT DOCUMENTS</b>										Applicant(s) Ilya Trakht					
										Filing Date September 18, 2000		Group Art Unit 1648			
<b>Examiner Initials</b>	<b>Exh. No.</b>	<b>Document Number</b>							<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>		
NEK	1	4	7	1	4	6	7	8	12/22/87	Reading et al.					
1	2	5	6	5	2	1	1	4	07/29/97	Chu et al.					
<b>FOREIGN PATENT DOCUMENTS</b>															
		<b>Document Number</b>							<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>		
														<b>Yes</b>	<b>No</b>
NEK	3	0	1	3	7	2	3	4	04/17/85	EPO					
1	4	0	6	9	5	7	6	0	02/07/96	EPO					
	5	0	7	9	9	8	3	6	10/08/97	EPO					
	6	9	4	2	7	6	3	8	12/08/94	PCT					
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>															
NEK	7	Carroll, W.L., Thielemans, K., Dilley, J. and Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89: 61-72; and													
1	8	Kearney, J.F., Radbruch, A., Liesegang, B. and Rajewsky K. (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550.													
<b>EXAMINER</b> <i>Nicole Kersay</i> <b>DATE CONSIDERED</b> <i>7/13/06</i>															
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

Applicants: Ilya Trakht  
 U.S. Serial No.: 09/664,485  
 Filed: September 18, 2000  
 Exhibit A



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
55099-A-PCT-  
US/JPW/AJM/AJDSerial No.  
09/664,485INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicant(s)  
Ilya TrakhtFiling Date  
September 18, 2000Group Art Unit  
1648

## U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No.	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ACK	1	Brodin T., Olsson L., Sjorgen H. (1983) Cloning of human hybridoma, myeloma, and lymphoma cell lines using enriched human monocytes as feeder layer, J. Immunol. Meth. 60: 1-7;
	2	Goldman-Leikin, R.E., Salawen, H.R., Herst, C.V., Variakojis, D., Bian, M.L., Le Beau, M.M., Selvanayagen, P., Marder R., Anderson, R., Weitzman, S., Rosen, S.T. (1989) Characterization of a novel myeloma line MM-1, J. Lab. Clin. Med. 113: 335-345;
	3	Kozbor, D., Roder, J.C. (1981) Requirements for the establishment of high titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique, J. Immunol. 127: 1275-1280;
	4	Kozbor, D., Tripputi, P., Roder, J.C., Croce, C.M. (1984) A human hybrid myeloma for production of human monoclonal antibodies, J. Immunol. 133: 3001-3005
	5	Levy, R., Miller, R.A. (1983) Tumor therapy with monoclonal antibodies, Fed. Proc. 42: 2650-2656;
	6	Nilsson, K., Ponten, J. (1975) Classification and biological nature of established human hematopoietic cell lines, Int. J. Cancer 15: 321-341;
	7	Oestberg, L., Pursch, E. (1983) Human x (mouse x human) hybridomas stably producing human antibodies, Hybridoma 2: 361-367;
	8	Posner, M.R., Schlossman, S.F., Lazarus, H. (1983) Novel approach to the construction of human "myeloma analogues" for the production of human monoclonal antibodies, Hybridoma 2: 369-381;

EXAMINER

Nicole Kersay

DATE CONSIDERED

7/13/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
55099-A-PCT-  
US/JPW/AJM/AJDSerial No.  
09/664,485INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicant(s)  
Ilya TrakhtFiling Date  
September 18, 2000Group Art Unit  
1648

## U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No.	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NEK	9	Reading, C.L. (1982) Theory and methods for immunization in culture and monoclonal antibody production, J. Immunol. 53: 261-291;
	10	Raison, R.L., Walker, K.Z., Halnan, C.R.E., Briscoe, D., Basten, A. (1982) Loss of secretion in mouse-human hybrids need not be due to the loss of a structural gene, J. Exp. Med. 156: 1380-1389;
	11	Teng, N.N.H., Lam, K.S., Riera, F.C., Kaplan, H.S. (1993) Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. (U.S.A.) 80: 7308-7311; and
	12	Weiss, M.C., Green, H. (1967) Human mouse hybrid cell lines containing partial complements of human chromosomes and functioning human genes, Proc. Natl. Acad. Sci. (U.S.A.) 58: 1104-1111.

EXAMINER

*Nicole Kensing*

DATE CONSIDERED

7/13/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.